← Eichor
Study identifier: NCT06620835 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

Condition: NSCLC  ·  Sponsor: Groupe Francais De Pneumo-Cancerologie

PhasePhase 2
Planned participants45
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn if the treatment by systemic Brigatinib (ALUNBRIG®) associated to local ablative therapy (LAT) treatment is improved if administered when the brigatinib works best in participants presenting an advanced non-small cells lung cancer with an ALK gene anomaly (this anomaly produces a defective protein that is responsible for the multiplication of cancer cells). This clinical trial is expected to involve 45 participants in several sites in France. Advanced non-small cell lung cancer (NSCLC) participants with ALK rearrangements treated with brigatinib in first line of non-curable setting will be screened. If the disease assessment done between 3 to 9 months after initiation of brigatinib shows: * a tumor response or stabilization (according to RECIST 1.1) * a disease which meets the definition of an oligometastatic disease (five metastatic lesions or less and a maximum of two lesions per organ) * all tumor targets are accessible to a local ablative therapy (confirmed by an expert panel of clinicians before inclusion): surgery, stereotactic radiosurgery (SRS). For liver, adrenal, or other metastases, percutaneous thermal ablation will be accepted. Participants will be asked to visit the clinic: * for eligibility criteria assessment prior to LAT * for LAT * every 8 weeks for checkups and tests the first year after LAT * and then every 12 weeks, for a maximum period of 3 years. Eligible patients will benefit from local ablative therap…

This description comes directly from the study's public registry record.

Talk to the study team

Hubert CURCIO  ·  +330231455160  ·  h.curcio@baclesse.unicancer.fr

Soizic FERLANDIN  ·  +330663224789  ·  soizic_ferlandin@yahoo.fr

Always discuss trial participation with your own doctor first.

Locations (27)

CHU de BrestBrest, FranceNot Yet Recruiting
Centre François BaclesseCaen, FranceNot Yet Recruiting
CH Métropole-SavoieChambéry, FranceNot Yet Recruiting
Hôpital Louis PasteurColmar, FranceNot Yet Recruiting
Pneumologie Centre Hospitalier Intercommunal de CréteilCréteil, FranceNot Yet Recruiting
Centre Georges-François LeclercDijon, FranceNot Yet Recruiting
CH AnnecyÉpagny, FranceNot Yet Recruiting
Polyclinique de BloisLa Chaussée-Saint-Victor, FranceNot Yet Recruiting
CHD les OudariesLa Roche-sur-Yon, FranceNot Yet Recruiting
CHU DupuytrenLimoges, FranceNot Yet Recruiting
Centre Leon BérardLyon, FranceWithdrawn
Hôpital NordMarseille, FranceNot Yet Recruiting

+ 15 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06620835